Cambridge Innovation Capital

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatments. This approach has the potential to provide effective and safe therapies for neurological, inflammatory, and oncological conditions.

Salience Labs specializes in developing hybrid photonic-electronic chips tailored for artificial intelligence applications. Originating from extensive research at the University of Oxford and the University of Münster, the company focuses on silicon photonics to meet the increasing demands of AI workloads in data center infrastructure. Its flagship product, an optical switch, enables all-optical networking between computing nodes, effectively addressing data movement bottlenecks. By utilizing photons instead of electrons for data processing, Salience Labs' technology significantly reduces power consumption while enhancing processing speeds. This innovative approach aims to transform the hardware landscape necessary for maximizing AI capabilities, providing low-latency, high-bandwidth networking that accelerates job completion and lowers operational costs.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the accessibility of these technologies, allowing receivers to detect even the weakest signals during transmission. This innovation aims to expand the market reach of consumer electronics, making them more efficient and user-friendly.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

Nuclera is a biotechnology company specializing in an automated protein prototyping system aimed at enhancing drug discovery processes. Its eProtein Discovery system enables researchers to rapidly produce and test high-quality, soluble, and active proteins, significantly accelerating protein projects. By integrating technology such as cell-free protein synthesis and digital microfluidics, Nuclera provides a high-throughput platform for automated protein access. This innovative approach allows scientists to obtain reliable proteins within a short timeframe, facilitating faster progress in their research and contributing to more efficient drug development efforts.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Seldon is a company that specializes in machine learning deployment, providing a platform designed to enhance the efficiency of data science workflows. Its software allows machine learning engineering teams to transition from research and development to production with significant time savings. By utilizing prototyping algorithms and models, Seldon's technology can convert machine learning models into production-ready microservices, specifically REST and GRPC, facilitating faster data interpretation. The company serves a diverse range of large enterprises across various sectors, including technology, pharmaceuticals, automotive, finance, and retail. Additionally, Seldon is known for its open-source projects that focus on model serving, explanations, and monitoring, contributing to the deployment and management of machine learning models.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Cambridge GaN Devices specializes in the development and commercialization of gallium nitride (GaN) power devices aimed at improving energy efficiency in electronic applications. The company offers a variety of GaN-based semiconductor products that enhance power conversion and minimize energy loss across different systems. These advanced devices find applications in sectors such as renewable energy, electric vehicles, and consumer electronics, supporting the shift towards more sustainable technologies. Cambridge GaN Devices focuses on creating transistors that are faster, more compact, and more efficient than traditional silicon alternatives, thereby enabling industries to utilize tailored semiconductors for critical applications. The company collaborates with industry partners to promote innovation and facilitate the integration of its technology into the power semiconductor market.

Unlikely AI is a company focused on advancing artificial intelligence through an innovative approach. It develops technology that enhances the capabilities of AI, allowing it to interact effectively with users and provide explanations for its actions. This product-centric platform aims to create solutions that enable computers to perform tasks previously deemed impossible, positioning Unlikely AI as a forward-thinking player in the AI industry.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

Salience Labs specializes in developing hybrid photonic-electronic chips tailored for artificial intelligence applications. Originating from extensive research at the University of Oxford and the University of Münster, the company focuses on silicon photonics to meet the increasing demands of AI workloads in data center infrastructure. Its flagship product, an optical switch, enables all-optical networking between computing nodes, effectively addressing data movement bottlenecks. By utilizing photons instead of electrons for data processing, Salience Labs' technology significantly reduces power consumption while enhancing processing speeds. This innovative approach aims to transform the hardware landscape necessary for maximizing AI capabilities, providing low-latency, high-bandwidth networking that accelerates job completion and lowers operational costs.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic antibody drugs for pets. Founded in 2017, the company utilizes advanced scientific methods to create innovative therapies that enhance the health and well-being of companion animals. PetMedix offers specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce high-quality, therapeutic antibodies tailored specifically for pets. By leveraging over thirty years of expertise in drug development, PetMedix aims to provide effective medical solutions that meet the unique needs of animals, ensuring they receive appropriate care and treatment.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

Seldon is a company that specializes in machine learning deployment, providing a platform designed to enhance the efficiency of data science workflows. Its software allows machine learning engineering teams to transition from research and development to production with significant time savings. By utilizing prototyping algorithms and models, Seldon's technology can convert machine learning models into production-ready microservices, specifically REST and GRPC, facilitating faster data interpretation. The company serves a diverse range of large enterprises across various sectors, including technology, pharmaceuticals, automotive, finance, and retail. Additionally, Seldon is known for its open-source projects that focus on model serving, explanations, and monitoring, contributing to the deployment and management of machine learning models.

Congenica Ltd., established in 2012, specializes in developing and operating clinical data solutions for genetic diagnosis globally. Headquartered in Hinxton, UK, the company's core product is Sapientia, a clinical genomic analytics platform that integrates human DNA sequences with detailed clinical information. This enables clinicians and researchers to interpret genetic diseases accurately, facilitating clinical diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine applications such as creating disease registries, identifying patient populations for clinical studies, and discovering novel drug targets and biomarkers.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools like Tableau and Power BI, as well as data science environments such as Python Notebooks and Apache Spark. GeoSpock DB caters to a wide range of industries, from real-time logistics tracking to local service applications, unlocking valuable insights from diverse IoT data sources.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

CEDAR Audio is a leading company specializing in audio restoration and speech enhancement for various applications, including film, television, radio broadcasting, and audio forensic investigation. Established in 1988 in Cambridge, UK, following extensive research funded by the British Library National Sound Archive, the company maintains strong ties to Cambridge University, benefiting from the expertise of its Directors, including two university professors. CEDAR Audio is dedicated to advancing the science and technology of audio restoration, producing many of the industry's top products while actively engaging in research to develop innovative techniques. The company focuses on delivering high-quality customer support and has received numerous accolades for its service excellence. Its hardware-based restoration systems are designed to suppress noise in diverse live settings, such as conferences, performances, and sporting events, enabling sound recordists to achieve clean, noise-free audio production.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Nstream, founded in 2015 and based in California, specializes in advanced analytics software that processes edge data in real-time. The company's flagship product, SWIM EDX, transforms streaming data into actionable insights and predictions, addressing the complexities associated with big data. Nstream offers solutions tailored for a diverse range of clients, including original equipment manufacturers, service providers, enterprises, and Internet of Things (IoT) vendors. Its platform combines edge computing, machine learning, and self-training digital twins within a unique mesh architecture. Additionally, Nstream provides Swim Continuum, an open-core, enterprise-grade platform designed for building and managing continuous intelligence applications at scale. This platform enhances situational awareness and decision-making by delivering precise, relevant data through a stateful architecture that minimizes latency and optimizes performance for high-frequency data analytics. By integrating seamlessly with existing enterprise systems, Nstream enables organizations to improve productivity, reduce operational costs, and gain deeper insights into their business operations.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools like Tableau and Power BI, as well as data science environments such as Python Notebooks and Apache Spark. GeoSpock DB caters to a wide range of industries, from real-time logistics tracking to local service applications, unlocking valuable insights from diverse IoT data sources.

Cytora is a London-based company founded in 2014 that specializes in a configurable platform designed for commercial insurers to enhance their risk processing capabilities. The platform digitizes incoming risks and enriches them with both internal and external data sources. It evaluates these risks using various rules related to appetite and priority before directing them to downstream systems for either automated or manual underwriting. By leveraging artificial intelligence, Cytora's platform learns the patterns of different risks and loss outcomes over time, allowing insurers to assign a rank, score, and price to each property and organization. This approach aims to improve risk selection, pricing accuracy, and overall efficiency in underwriting processes.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

Secondmind Ltd. is a company that specializes in developing an online software platform utilizing machine learning algorithms to facilitate artificial intelligence-based decision-making. Founded in 2016 and based in Cambridge, United Kingdom, Secondmind offers the Secondmind Decision Engine, a cloud-based platform designed to assist users in predicting, planning, managing risks, and making complex decisions efficiently. The company aims to support automotive innovators in designing cleaner vehicles and achieving sustainability goals amidst the challenges of electrification. By providing advanced tools for automotive engineers, Secondmind helps navigate the complexities of engineering design, ultimately contributing to the transition towards carbon-neutral mobility. The company has garnered backing from prominent venture funds, reflecting its commitment to advancing machine learning applications in the automotive sector.

Z Factor Limited is a drug discovery company established in 2015, focusing on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company aims to design innovative treatments that correct the misfolding of the Z variant of alpha-1-antitrypsin. This condition currently has limited treatment options, primarily relying on lung or liver transplantation and augmentation therapy. Z Factor's mission addresses a significant unmet medical need by working to create effective alternatives for patients suffering from this deficiency.

Congenica Ltd., established in 2012, specializes in developing and operating clinical data solutions for genetic diagnosis globally. Headquartered in Hinxton, UK, the company's core product is Sapientia, a clinical genomic analytics platform that integrates human DNA sequences with detailed clinical information. This enables clinicians and researchers to interpret genetic diseases accurately, facilitating clinical diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine applications such as creating disease registries, identifying patient populations for clinical studies, and discovering novel drug targets and biomarkers.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Exvastat is a preclinical-stage pharmaceutical company established in 2016, focused on developing a treatment for acute respiratory distress syndrome (ARDS) using a repurposed drug already available for other medical indications. The company aims to address the significant mortality and debilitating complications associated with ARDS by inhibiting vascular leaks that contribute to pulmonary edema. By improving patient outcomes, Exvastat also seeks to lower the financial burden on healthcare providers caring for critically ill patients.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

PervasID Limited, founded in 2011 and based in Cambridge, United Kingdom, specializes in the development of wide area passive RFID systems. The company emerged from research conducted at the University of Cambridge and focuses on providing location capabilities based on the EPC Class1 Gen2 standard. PervasID's technology employs fixed ultra-high frequency RFID to accurately detect passive tags over long distances, facilitating enhanced visibility into goods, assets, and people. Its innovative systems are designed to serve various industries, including retail, healthcare, supply chain and logistics, and aviation. The technology has been successfully deployed in multiple field trials, demonstrating its reliability and effectiveness in streamlining processes across diverse markets.

Fluidic Analytics Limited, established in 2013 as a spin-out from the University of Cambridge's Department of Chemistry, specializes in designing and manufacturing advanced tools for protein characterization. The company offers innovative products, including Fluidity One and Fluidity One-W, which facilitate in-solution sizing and quantification of native proteins, as well as high-sensitivity analysis of protein interactions and kinetics. These tools are essential for applications such as assessing protein quality, interactions, and aggregation. Targeting scientists, clinics, and healthcare providers, Fluidic Analytics aims to enhance the understanding of protein behavior and function, paralleling the transformative impact of DNA sequencing in biology. With a commitment to accessibility and collaboration, the company strives to create a community that fosters open exchange and empowers users with complete ownership of their data. By combining cutting-edge technology with a dedicated team, Fluidic Analytics is positioned to advance the field of protein science significantly.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools like Tableau and Power BI, as well as data science environments such as Python Notebooks and Apache Spark. GeoSpock DB caters to a wide range of industries, from real-time logistics tracking to local service applications, unlocking valuable insights from diverse IoT data sources.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.

Abcodia Ltd. is a biotechnology company that specializes in the discovery and validation of molecular biomarkers to enhance disease diagnosis and screening, particularly for cancer. The company offers the Roca Test, which is designed for early detection of ovarian cancer, serving clients across various states in the United States as well as in the United Kingdom. Abcodia leverages a unique longitudinal serum biobank and collaborates with institutions like University College London and major diagnostic firms to facilitate comprehensive diagnostic development. Founded in 2010, Abcodia is headquartered in London, United Kingdom.

Undo Ltd. specializes in developing advanced debugging tools aimed at enhancing software development processes for professionals such as developers, software architects, and product managers. The company offers innovative solutions like LiveRecorder, which records and replays software execution, allowing users to identify and resolve programming errors effectively. Additionally, UndoDB serves as an interactive reversible debugger for C/C++ applications on Linux and Android platforms. By employing time travel debugging technology, Undo enables developers to gain insights into complex code, facilitating the diagnosis of new regressions, legacy bugs, and flaky tests prior to customer impact. The company primarily caters to industries including data management, networking, electronic design automation, and finance. Founded in 2005, Undo Ltd. operates from its headquarters in Cambridge, United Kingdom, and maintains an additional office in San Francisco, California.

Congenica Ltd., established in 2012, specializes in developing and operating clinical data solutions for genetic diagnosis globally. Headquartered in Hinxton, UK, the company's core product is Sapientia, a clinical genomic analytics platform that integrates human DNA sequences with detailed clinical information. This enables clinicians and researchers to interpret genetic diseases accurately, facilitating clinical diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine applications such as creating disease registries, identifying patient populations for clinical studies, and discovering novel drug targets and biomarkers.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Congenica Ltd., established in 2012, specializes in developing and operating clinical data solutions for genetic diagnosis globally. Headquartered in Hinxton, UK, the company's core product is Sapientia, a clinical genomic analytics platform that integrates human DNA sequences with detailed clinical information. This enables clinicians and researchers to interpret genetic diseases accurately, facilitating clinical diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine applications such as creating disease registries, identifying patient populations for clinical studies, and discovering novel drug targets and biomarkers.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Origami specializes in developing trading and automation software for the energy sector, focusing on the management of distributed energy assets. The company aims to facilitate a transition to a greener energy world through innovative technology. Its real-time data platform incorporates advanced machine learning tools that help energy companies navigate the complexities of modern energy markets. By providing decision support systems, Origami enables clients to enhance visibility, minimize risks, and seize opportunities in evolving energy landscapes. The company's solutions are designed to optimize trading operations and improve profitability across various stages of power production and energy trading, ultimately supporting a more efficient and resilient energy ecosystem.

Jukedeck Limited is a London-based company that specializes in creating soundtracks for videos through artificial intelligence. Established in 2012, the company has developed technology that composes and adapts personalized music for various contexts, allowing users to generate original music autonomously. Jukedeck also offers an API that grants access to a library of royalty-free music, enabling users to create, browse, and edit their own soundtracks. This innovative approach utilizes deep neural networks to understand and facilitate music composition, enhancing creative processes for users. As of July 2019, Jukedeck operates as a subsidiary of Bytedance UK Limited.

Imagen Ltd specializes in media archive management solutions, providing tools for content owners to manage, search, and distribute their media libraries effectively. Its offerings include Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based platform for video and image management; and Orbital, a system designed for compliance recording. The company serves a diverse clientele, including the Ministry of Defence, The Police, the BBC, ITN, the Imperial War Museum, British Telecom, and British Pathe. Founded in 1991 and based in Willingham, United Kingdom, Imagen was previously known as Cambridge Imaging Systems Limited before rebranding in August 2015. The company's modular enterprise video platform supports businesses of all sizes in monetizing their media archives.